Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions There is no evidence regarding quality of life, patient reported outcome measures or patient reported experience measures to determine whether atezolizumab provides clinically significant improvement in the symptoms or severity of NSCLC. Results from the OAK (phase III) randomized, open-label trial hold limited external validity as participants are not entirely generalisable to clinical practice. Longer trials are needed which directly compare the safety and efficacy of atezolizumab versus other immunotherapies such as nivolumab or pembrolizumab, or docetaxel in combination with nintedanib or ramucirumab. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; atezolizumab Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32017000330 Date abstract record published 01/08/2017 |